Chemokines and the arrest of lymphocytes rolling under flow conditions

Science

Volumn 279, Issue 5349, 1998, Pages 381-384

  Campbell, James J ^a,b   Hedrick, Joseph ^c   Zlotnik, Albert ^c   Siani, Michael A ^d   Thompson, Darren A ^d   Butcher, Eugene C ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ctr for Molec Biology and Medicine   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Gryphon Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; INTERCELLULAR ADHESION MOLECULE 1;

ARTICLE; BLOOD FLOW; CELL ADHESION; CELL MIGRATION; CIRCULATION; CROSS LINKING; HUMAN; LYMPHOCYTE; PRIORITY JOURNAL;

ANTIGENS, SURFACE; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CHEMOKINES, CC; CHEMOKINES, CXC; HUMANS; IMMUNOLOGIC MEMORY; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTES; MACROPHAGE INFLAMMATORY PROTEINS; MEMBRANE PROTEINS; RECEPTORS, CHEMOKINE; RHEOLOGY;

EID: 0032536046     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5349.381     Document Type: Article

References (44)

1. E. C. Butcher, Cell 67, 1033 (1991).
2. Y. Shimuzu, W. Newman, Y. Tanaka, S. Shaw, Immunol. Today 13, 106 (1992).
3. T. M. Carlos and J. M. Harlan, Blood 84, 2068 (1994).
4. T. J. Schall and K. B. Bacon, Curr. Opin. Immunol. 6, 865 (1994).
5. A. Imhof and D. Dunon, Adv. Immunol. 58, 345 (1995).
6. T. A. Springer, Annu. Rev. Physiol. 57, 827 (1995).
7. E. C. Butcher and L. J. Picker, Science 272, 60 (1996).
8. U. von Andrian et al., Am. J. Physiol. 263, H1034 (1992).
9. U. R. von Andrian et al., Proc. Natl. Acad. Sci. U.S.A. 88, 7538 (1991).
10. R. F. Bargatze and E. C. Butcher, J. Exp. Med. 178, 367 (1993).
11. R. A. Warnock, S. Askari, E. C. Butcher, U. H. von Andrian, ibid., in press.
12. A. R. Lloyd, J. J. Oppenheim, D. J. Kelvin, D. D. Taub, J. Immunol. 156, 932 (1996).
13. D. D. Taub, K. Conlon, A. R. Lloyd, J. J. Oppenheim, D. J. Kelvin, Science 260, 355 (1993).
14. Y. Tanaka et al., Nature 361, 79 (1993).
15. D. D. Taub et al., J. Exp. Med. 177, 1809 (1993).
16. M. W. Carr, R. Alon, T. A. Springer, Immunity 4, 179 (1996).
17. R. F. Bargatze, thesis, Montana State University, Bozeman, MT (1994).
18. S. Honda et al., J. Immunol. 152, 4026 (1994).
19. J. J. Campbell, S. Qin, K. B. Bacon, C. R. Mackay, E. C. Butcher, J. Cell Biol. 134, 255 (1996).
20. J. J. Campbell, E. F. Foxman, E. C. Butcher, Eur. J. Immunol. 27, 2471 (1997).
21. K. Tashiro et al., Science 261, 600 (1993).
22. C. C. Bleul, R. C. Fuhlbrigge, J. M. Casanovas, A. Aiuti, T. A. Springer, J. Exp. Med. 184, 1101 (1996).
23. J. F. Bazan et al., Nature 385, 640 (1997).
24. Y. Pan et al., ibid. 387, 611 (1997).
25. D. L. Rossi, A. P. Vicari, K. Franz-Bacon, T. McClanahan, A. Zlotnik, J. Immunol. 158, 1033 (1997).
26. R. Yoshida et al., J. Biol. Chem. 272, 13803 (1997).
27. J. A. Hedrick and A. Zlotnik, J. Immunol. 159, 1589 (1997).
28. R. Hromas et al., Blood 89, 3315 (1997).
29. M. Baba et al., J. Biol. Chem. 272, 14893 (1997).
30. K. Heishima et al., ibid., p. 5846.
31. G. J. Adema et al., Nature 387, 713 (1997).
32. K. Heishima et al., J. Immunol. 159, 1140 (1997).
33. T. Imai, M. Baba, M. Nishimura, S. Takagi, O. Yoshie, J. Biol. Chem. 272, 15036 (1997).
34. 2 for 30 min in RPMI 1640 medium supplemented with 10% calf serum. Recombinant human eotaxin, MIP-1α, MIP-1β, RANTES, MCP-1, MCP-3, IP-10, IL-8, GRO-α, C-X3-C-kine, DC-CK-1, MIP-3α, MIP-3β, 6-C-kine, I-309, SDF-1β, lymphotactin, and TARC were obtained from R&D Systems (Minneapolis, MN) or PeproTech (Rocky Hill, NJ). Recombinant IL-8 was also provided by A. Rott (Sandoz, Vienna). Synthetic human SDF-1α, MIP-3α, MIP-3β, TARC, and C-X3-C-kine were also prepared by two of the authors (M.A.S. and D.A.T.) by chemical ligation [P. E. Dawson, T. W. Muir, I. dark-Lewis, S. H. B. Kent, Science 266, 776 (1994). Synthetic SDF-1α was also provided by I. dark-Lewis. Chemokines were shown to be active by chemotaxis of human peripheral blood lymphocytes, eosinophils, or neutrophils, or of chemokine receptor-overexpressing lymphoma cell lines. There were no detectable differences among chemokines obtained from different sources in these assays.
35. 2 for 30 min in RPMI 1640 medium supplemented with 10% calf serum. Recombinant human eotaxin, MIP-1α, MIP-1β, RANTES, MCP-1, MCP-3, IP-10, IL-8, GRO-α, C-X3-C-kine, DC-CK-1, MIP-3α, MIP-3β, 6-C-kine, I-309, SDF-1β, lymphotactin, and TARC were obtained from R&D Systems (Minneapolis, MN) or PeproTech (Rocky Hill, NJ). Recombinant IL-8 was also provided by A. Rott (Sandoz, Vienna). Synthetic human SDF-1α, MIP-3α, MIP-3β, TARC, and C-X3-C-kine were also prepared by two of the authors (M.A.S. and D.A.T.) by chemical ligation [P. E. Dawson, T. W. Muir, I. dark-Lewis, S. H. B. Kent, Science 266, 776 (1994). Synthetic SDF-1α was also provided by I. dark-Lewis. Chemokines were shown to be active by chemotaxis of human peripheral blood lymphocytes, eosinophils, or neutrophils, or of chemokine receptor-overexpressing lymphoma cell lines. There were no detectable differences among chemokines obtained from different sources in these assays.
36. - subpopulations.
37. C. R. Mackay, Adv. Immunol. 53, 217 (1993).
38. M. E. Sanders et al., J. Immunol. 140, 1401 (1988).
39. E. L. Berg, L. M. McEvoy, C. Berlin, E. C. Butcher, Nature 366, 695 (1993); U. H. von Andrian, S. R. Hasslen, R. D. Nelson, S. L. Erlandsen, E. C. Butcher, Cell 82, 989 (1995).
40. E. L. Berg, L. M. McEvoy, C. Berlin, E. C. Butcher, Nature 366, 695 (1993); U. H. von Andrian, S. R. Hasslen, R. D. Nelson, S. L. Erlandsen, E. C. Butcher, Cell 82, 989 (1995).
41. M. B. Lawrence, E. L. Berg, E. C. Butcher, T. A. Springer, Eur. J. lmmunol. 25, 1025 (1995).
42. 2) = mean flow velocity (mm/s) × [8/tube diameter (mm)] × viscosity (poise).} The interactions of cells with the coated areas were recorded on videotape, and the behavior of individual cells was analyzed frame by frame.
43. C. Berlin et al., Cell 80, 413 (1995).
44. We thank I. Clark-Lewis, U. H. von Andrian, and D. P. Andrew for synthetic SDF-Iα, PNAd, and ICAM-1, respectively, used in preliminary experiments; E. P. Bowman, K. Youngman, and M. Hubbe for help with preliminary experiments and discussions; L. Rott and G. Haraldson for advice on cell separation; and S. Haugejorden-Brown, E. P. Bowman, E. F. Foxman, and R. A. Warnock for critical reading of the manuscript. Supported by NIH grant GM37734 and an award from the Department of Veterans Affairs (E.C.B.); NIH grant DK38707 to the FACS Core Facility of the Stanford Digestive Disease Center, and NIH Cancer Etiology, Prevention, Detection, and Diagnosis grant 5T32CA090302, NIH grant 1F32AI08930, and the Arthritis Foundation (J.J.C.).